anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The effects of administered vitamin D can persist for two or more months after cessation of treatment.

Hypervitaminosis D is characterized by:

  1. Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis.
  2. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death.
  3. Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly.
  4. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism).



The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported.

The LD50 in animals is unknown. The toxic oral dose of ergocalciferol in the dog is 4 mg/kg.
Previous study has demonstrated that the Dietary Inflammation Index (DII) played a role in the risk of inflammatory bowel disease (IBD), however, the prevalence and risk factors for IBD are distinct across locations and groups, and therefore, the findings are debatable and warrant further investigation. A total of 4363 participants were calculated in the National Health and Nutrition Examination Survey (NHANES) 2009 to 2010, of whom 1.21% self-reported a history of IBD. DII values were performed as a good predictor of dietary inflammation based on data from two 24-h dietary reviews in the NHANES database. Comparing the multifarious effects along with variations of the whole population by grouping populations according to DII quartiles, dietary inflammation levels increased progressively from DII quartile 1(Q1) to quartile 4(Q4). The association between DII and IBD was tested with multi-variable logistic regression models, subgroup analyses and weighted generalized additive models. Participants in the Q4 group showed the highest levels of C-reactive protein and reduced haemoglobin and albumin levels. Logistic regression confirmed the odds ratios (95% confidence intervals) of IBD for DII were 0.99 (0.86, 1.15), 0.97 (0.84, 1.13) and 0.80 (0.66, 0.98) in models 1, 2 and 3, respectively. The negative correlation between DII and IBD among United States adults from the NHANES database became increasingly apparent as covariates were adjusted. Subgroup analyses and smoothed curve fitting confirmed the inverse results. The study revealed that DII was correlated with the overall physical well-being of participants. However, there was no significant association between DII and IBD.
Cirrhosis represents the end stage of chronic liver disease. Sub-Saharan Africa, a resource-constrained region, has a high burden of chronic liver disease, with causes including chronic viral hepatitis, excessive alcohol use, and metabolic dysfunction-associated steatotic liver disease (MASLD), the risk of which is burgeoning. The development of liver cirrhosis predicts for morbidity and mortality, driven by both liver dysfunction and the consequences of portal hypertension. Compensated cirrhosis portends a better prognosis than decompensated cirrhosis, highlighting the need for the early diagnosis of cirrhosis and its causes. With resource challenges, the diagnosis and management of cirrhosis is demanding, but less costly and less invasive interventions with substantial benefits, ranging from simple blood tests to transient elastography, are feasible in such settings. Simple interventions are also available to manage the complex manifestations of decompensation, such as β blockers in variceal bleeding prophylaxis, salt restriction and appropriate diuretic use in ascites, and lactulose and generic rifaximin in hepatic encephalopathy. Ultimately, managing the underlying causative factors of liver disease is key in improving prognosis. Management demands expanded policy interventions to increase screening and treatment for hepatitis B and C and reduce alcohol use and the metabolic factors driving MASLD. Furthermore, the skills needed for more specialised interventions, such as transjugular intrahepatic portosystemic shunt procedures and even liver transplantation, warrant planning, increased capacity, and support for regional centres of excellence. Such centres are already being developed in sub-Saharan Africa, demonstrating what can be achieved with dedicated initiatives and individuals.
PROBLEM TO BE SOLVED: To obtain a health nutritive food having a comprehensively remarkable health-stimulating effect and good in storage stability. SOLUTION: This health nutritive food is obtained by compounding a horse oil with one or more kinds of nutritive elements. The horse oil is obtained by pressing or boiling the mane, tail base part or subcutaneous fat layer of a horse or their mixture, subjecting the obtained oil fraction to decolorization, dehydration and filtration treatments, and further subjecting the treated product to a deodorizing treatment. The nutritive elements comprise the mixture of garlic, carrot, calcium, squalene and soybean oil. Although the amounts of the compounded components are especially not limited, the doses of the horse oil, the garlic, the carrot, the calcium, the squalene and the soybean oil are suitably approximately 50-500mg, 1-50mg, 10-100mg, 10-100mg, 10-100mg,10-150mg, respectively.  A natural antioxidizing deterioration-inhibiting agents such as ellagic acid or γ-orizanol, an antiseptic preservative such as benzoic acid or sodium benzoate, and a filling vehicle for solidifying the food, such as beeswax, may be compounded.
PROBLEM TO BE SOLVED: To obtain a detergent composition for washing hair excellent in foaming and conditioning abilities and further in antiseptic ability and preservation stability by using an oily material together with a specific organic acid or its salt. SOLUTION: In this detergent composition, an oily material and a water soluble lower alkanoic acid or its salt are added as essential ingredients. As the water soluble lower alkanoic acid or its salt, especially propionic acid or its salt are suitable. As the oily material, fatty acid esters, above all, a propylene glycol ester of a fatty acid expressed by the formula [X1 and X2 are each a COR (R is an alkyl or an alkenyl) or H and at least one of X1 and X2 is COR] is suitable. The amount of the oily material to be added is preferably 0.1-5wt.% based on the total amount of the composition. The amount of the lower alkanoic acid or its salt to be added is preferably 0.001-2wt.%.
Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
An edible matrix composition that has a chewable texture and that contains at least one encapsulated component is obtained by admixing at least one plasticizer, and a ground, free-flowing particulate mixture which comprises at least one fat, at least one starch, and at least one sugar which have been mixed and heated without substanitially gelatinizing the starch. A chewable texture is obtained rather than a hard, glassy matrix because the starch is substantially ungelatinized. However, a flavorful product is obtained without destroying a heat sensitive encapsulant because the starch is admixed with ingredients comprising fat or oil and sugar and the mixture is heated to develop flavor at high temperatures prior to admixing with the heat sensitive encapsulant. The encapsulated component may be at least one biologically active component, pharmaceutical component, nutraceutical component, or microorganism. In preferred embodiments, the free-flowing mixture is obtained by grinding cookies. The free-flowing mixture, such as ground cookies and the plasticizer, such as oil and water are mixed with an encapsulant to obtain a formable dough or crumbly mass. The formable dough is shaped or formed into pieces or pellets and dried to a shelf-stable moisture content
TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
Thyroid storm is an endocrine emergency, and treatment must ensure primary goals, including reducing the production and release of thyroid hormones, mitigating the effects of thyroid hormones, increasing the elimination of thyroid hormones, treating systemic disturbances, and managing triggering factors. However, in a few cases where thyroid storm does not respond to initial treatment, therapeutic plasma exchange (TPE) should be considered. A 50-year-old male patient was admitted to the University Medical Center Ho Chi Minh City due to hypotonia and sensory disturbances gradually spreading from the lower extremities to the entire body. The patient was diagnosed with Guillain-Barré syndrome (GBS) and newly discovered hyperthyroidism. During the treatment course, the patient developed hospital-acquired pneumonia, acting as a trigger factor for a thyroid storm. Despite aggressive treatment for thyroid storm, the patient's condition worsened, leading to the decision to perform TPE. The replacement fluid was a combination of fresh frozen plasma (FFP) and albumin 5%. Subsequently, the patient returned to a euthyroid state and was discharged. Combining FFP and albumin 5% in TPE advantages FFP's high thyroid hormones-binding capacity and albumin's cost-effectiveness, safety, and efficiency. This reduces the drawbacks associated with high volumes of FFP and offers a balanced and effective approach to managing thyroid storms. Moreover, the concurrent presence of GBS and thyroid storm is extremely rare. Through this case, we aim to discuss the role of TPE in the treatment of thyroid storms and the effectiveness of the combination of FFP and albumin 5% as the replacement fluid.
Matrix metalloproteinase (MMP)-12 has been reported to have diverse functions, including regulation of immune reactions and anti-inflammatory effects, but the potential roles of MMP-12 in kidney injury have not been fully elucidated. This study aimed to determine whether MMP-12 contributes to tubulointerstitial injury in a unilateral ureteric obstruction (UUO) model. MMP-12-deficient (MMP-12-/-) mice and C57BL/6J mice as controls (MMP-12+/+) were subjected to UUO and analysed 7 days after UUO. To analyse the functions of MMP-12 on monocytes/macrophages, we generated MMP-12-deficient, irradiated, chimeric mice (BM-MMP-12-/-) and performed UUO. Bone marrow-derived macrophages (BMDMs) were isolated from both groups of mice and used for investigations. MMP-12-/- mice showed exacerbation of macrophage accumulation and interstitial fibrosis in the UUO-kidney compared with control mice. BM-MMP-12-/- mice also showed exacerbation of kidney injury. UUO induced accumulation of Ly6C+ macrophages in MMP-12-/- mice compared with control mice. Increases in inflammatory cytokine (tumour necrosis factor α, interleukin [IL]-1β, IL-6) levels from BMDMs after lipopolysaccharide stimulation were higher in MMP-12-/- mice than in MMP-12+/+ mice. MMP-12 may play protective roles against kidney injury by UUO in mice, decreasing inflammatory cytokines from BMDMs and macrophage accumulation.
This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
A transdermal patch useful for evaluating the therapeutic effectiveness of a transdermally delivered medicinal agent is disclosed. The patch (11) includes a substantially impermeable backing layer (13), a delivery layer (14) containing a medicament (15) and a substantially impermeable blocking layer (16). The delivery layer is arranged between the backing and blocking layers to prevent the release of the medicament contents from the delivery layer when the transdermal patch is affixed to the skin of a mammal. In alternative embodiments, non-transdermal placebo systems such as oral dosage forms which are coated with substantially impermeable layers to create virtually identical placebos of active oral delivery systems such as tablets, capsules and osmotic tablets are disclosed. Methods of comparing the therapeutic effectiveness of active dosage forms, i.e. transdermal units containing a medicament to placebo or to comparable active agents in either similar or different delivery systems are also disclosed.
Provided is a method of establishing a model for analyzing the correlation of the white coat effect. For each of a plurality of testers, the physiological data, medication data and labeling results corresponding to the tester are used as a set of training data. Then, based on the training data, an interpretable machine learning algorithm is used to obtain a correlation model and a plurality of influence levels. Next, from each set of training data, the item with the lowest impact is removed, and a machine learning algorithm and a verification method are used to obtain a white coat effect correlation model and a model evaluation value based on the training data after removal. Furthermore, the item corresponding to the lowest impact is removed, and another white coat effect correlation model and another model evaluation value are obtained. Finally, a target white coat effect correlation model is obtained based on these model evaluation values.
<P>PROBLEM TO BE SOLVED: To provide an antiviral agent-supporting sheet which can maintain antiviral activity such as anti-influenza virus activity for a long time.  <P>SOLUTION: This supporting sheet comprises adhering antiviral agents such as an anti-influenza virus agent of the shape of a fine particle which generate a hydroxy radical by an adhesive to a sheet-like article. Dolomite is fired, hydrated, then ground to be a fine particle and is used as the fine particle-like antiviral agent. The adhesive includes polyvinyl alcohol of the polymerization degree of 250-1,000. The degree of saponification of the polyvinyl alcohol is desirably 35-99 mol%. The adhesive may further includes a polyolefin resin of the shape of a fine particle having a number-average particle diameter of 1 μm or less. Moreover, nonwoven fabric, knit/woven fabric, paper or the like is used as the sheet-like article.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The purpose of this study is to use a closed-loop Control-to-Range (CTR) system in adolescents with type 1 diabetes in an outpatient setting, and to evaluate the CTR system's ability to significantly improve blood glucose levels when an insulin bolus is omitted for a 30 gram carbohydrate snack and when insulin bolus is insufficient for the amount of carbohydrates consumed for a meal. The CTR system is comprised of two algorithmic layers: (i) A Safety Supervision Module (SSM) which contains a predictive insulin request dampener (or brakes); (ii) a Range Correction Module (RCM), consisting in (a) a Hyperglycemia Mitigation System, and (b) Insulin on Board controller. Both modules will receive continuous glucose monitoring (CGM) and historical insulin delivery data. The SSM will monitor the safety of the subject's continuous subcutaneous insulin infusion pump (CSII) to prevent hypoglycemia. The RCM will be responsible for optimizing blood glucose (BG) control and mitigating postprandial hyperglycemic excursions through a mix of increased basal rate and, potentially, isolated insulin boluses. To run CTR, we will use our wearable artificial pancreas platform, known as DiAs (Diabetes Assistant) which consists of a smart phone running CTR and connected to standard insulin delivery and CGM devices.
Abstract Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation there-of, and pharmaceutical compositions containing them.            Disclosed are novel derivatives of polyene macrolide antibiotics of the general formula       (I) wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is (II),   (III), -R5 or hydrogen, wherein A and B independently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is -NH-?-R-NR3R4, R5 is an .alpha.-amino-acyl group; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; z is zero or 1, and Y is hydrogen,    alkyl, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen, z must be 1 and Y allyl, propargyl, benzyl or phenylpropargyl; and the pharmaceutically acceptable acid addition salts thereof.            The novel compounds may be prepared by methods known per se.  Preferably the compounds are prepared by reaction of respective polyene macrolide antibiotic with a reactive derivative of a compound HOX' wherein the amino group(s) is(are) protected.  The compounds wherein X is hydrogen and Y is allyl, propargyl, benzyl or phenylpropargyl can be prepared by reaction of the respective N-protected polyene macrolide antibiotic with  a  reactive derivative of propene, propyne, phenylpropyne or toluene.            The compounds show antifungal activity and are useful in the treatment of fungal infections.
PROBLEM TO BE SOLVED: To provide a composition for treating hair by adding an exogenous enzyme, an alcohol and an acid or triglyceride thereof, and to provide a method of treating hair by using the composition. SOLUTION: This composition for treating hair comprises at least one of exogenous enzyme that can cause an enzymatic reaction directly in the hair, a long-chain alcohol and a long-chain acid or a triglyceride thereof. This composition is used to treat a keratin substance, e.g. hair. The enzyme is capable of inducing esterification, particularly selected from lipase, esterase and protease. The treatment of hair with this composition enhances the appearance of the hair fiber, namely the flexibility and the gloss and facilitates the hairstyling.
Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
Through more than forty years of clinical practice and experience and by combining modern medical knowledge, an experience formula composed of ten traditional Chinese medicines (No. 1) including radix astragali, uncaria, prunella vulgaris, cassia twig, gingko leaf and the like, No.2 (ten traditional Chinese medicines) and No. 3 (11 traditional Chinese medicines) has been prepared. The experience formula has effects of clearing away heat and drying dampness, clearing liver fire, purging fire for removing toxin, calming endogenous wind and relieving convulsion, clearing heat and calming the liver, eliminating hepatic depression, reducing blood pressure, dispelling wind and clearing heat, relieving internal heat or fever and improving eyesight, nourishing Yin and suppressing Yang, tonifying the kidney and invigorating bone, nourishing blood and tonifying heart, rescuing from collapse by restoring Yang, tonifying fire and helping yang, eliminating cold to stop pain, removing heat to cool blood, invigorating the circulation of blood and dissipating blood stasis, astringing and inducing astringency, clearing damp and promoting dieresis, tonifying spleen, soothing the nerves, reducing heat and tonifying spleen, lung and kidney. Through thousands of clinical cases, curative effect of the formula reaches 90% and above. The experience formula has an additional curative effect of treating hypertension, which isn't involved in products of the same kind. Usage and dosage for adults: usual dose according to the code of medicine is used and increased or reduced according to symptoms.
Participants randomly assigned to the wait list control group, will perform baseline testing and be instructed not to change their exercise habits. After 6 weeks participants will complete post-testing (described below) and be offered to be enrolled in the 6-week exercise group as described above. If participants decide to participate in the exercise group and still meet the inclusion and exclusion criteria, they will perform baseline testing, 6 weeks of exercise followed by another post-testing.
Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
FIELD: medicine, pharmacology. SUBSTANCE: invention relates to agents inhibiting transport of cationic amino acids and discloses rabbit antiserum induced against T-cellular protein encoded by gene mCAT-2 (murino Cationic amino acid fransporter). Invention relates to also the pharmaceutical composition containing indicated antiserum. Invention provides inhibition of transport of cationic amino acids. EFFECT: valuable properties of antiserum. 2 cl, 22 dwg, 5 tbl
Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.